Pacira Historical Income Statement

PCRX Stock

USD 27.21 0.11 0.40%

Historical analysis of Pacira Pharmaceuticals income statement accounts such as Gross Profit of 454.7 M, Other Operating Expenses of 617 M, Operating Income of 91.7 M or Ebit of 91.7 M can show how well Pacira Pharmaceuticals performed in making a profits. Evaluating Pacira Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Pacira Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Pacira Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Pacira Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacira Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pacira Stock please use our How to Invest in Pacira Pharmaceuticals guide.

About Pacira Income Statement Analysis

Pacira Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Pacira Pharmaceuticals shareholders. The income statement also shows Pacira investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Pacira Pharmaceuticals Income Statement Chart

Pacira Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Pacira's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Pacira Pharmaceuticals revenue and expense. Pacira Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.

At this time, Pacira Pharmaceuticals' Income Tax Expense is fairly stable compared to the past year. Net Income From Continuing Ops is likely to rise to about 7.3 M in 2024, whereas Interest Expense is likely to drop slightly above 16.1 M in 2024.

Total Revenue Other Operating Expenses Research Development Total Operating Expenses

Total Revenue

Total revenue comprises all receipts Pacira Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Pacira Pharmaceuticals. It is also known as Pacira Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Pacira Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Pacira Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacira Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pacira Stock please use our How to Invest in Pacira Pharmaceuticals guide.At this time, Pacira Pharmaceuticals' Income Tax Expense is fairly stable compared to the past year. Net Income From Continuing Ops is likely to rise to about 7.3 M in 2024, whereas Interest Expense is likely to drop slightly above 16.1 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	31.8M	40.0M	23.8M	16.1M
Depreciation And Amortization	13.6M	61.4M	75.6M	79.4M

Interest Expense Depreciation And Amortization

Pacira Pharmaceuticals income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Net Income From Continuing Ops	Non Recurring	Non Operating Income Net Other	Selling And Marketing Expenses	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation
Depreciation And Amortization		0.49	0.64	0.83	0.76	0.85	0.65	0.65	0.55	0.82	0.93	0.59	0.74	-0.33	0.47	0.18	0.28	-0.81	-0.39	0.64	0.03	0.18	-0.53	0.98
Interest Expense	0.49		0.85	0.82	0.87	0.79	0.79	0.79	0.88	0.76	0.66	0.91	0.66	-0.82	0.62	-0.16	0.62	-0.09	-0.04	0.87	-0.19	-0.26	-0.96	0.5
Selling General Administrative	0.64	0.85		0.87	0.89	0.87	0.78	0.77	0.92	0.79	0.78	0.95	0.75	-0.64	0.6	-0.02	0.54	-0.24	0.0	0.94	-0.09	-0.13	-0.78	0.6
Total Revenue	0.83	0.82	0.87		0.99	0.99	0.9	0.89	0.82	0.95	0.96	0.88	0.89	-0.69	0.66	0.05	0.55	-0.59	-0.18	0.92	-0.07	-0.13	-0.8	0.78
Gross Profit	0.76	0.87	0.89	0.99		0.98	0.92	0.91	0.84	0.94	0.92	0.9	0.88	-0.74	0.69	0.01	0.59	-0.51	-0.12	0.94	-0.09	-0.17	-0.84	0.72
Other Operating Expenses	0.85	0.79	0.87	0.99	0.98		0.84	0.83	0.83	0.91	0.97	0.88	0.83	-0.63	0.62	0.05	0.5	-0.6	-0.17	0.92	-0.07	-0.11	-0.77	0.81
Operating Income	0.65	0.79	0.78	0.9	0.92	0.84		1.0	0.67	0.96	0.82	0.75	0.96	-0.82	0.74	0.03	0.65	-0.49	-0.19	0.79	-0.07	-0.16	-0.81	0.59
Ebit	0.65	0.79	0.77	0.89	0.91	0.83	1.0		0.67	0.97	0.81	0.73	0.95	-0.84	0.74	0.02	0.65	-0.5	-0.21	0.78	-0.08	-0.14	-0.82	0.6
Research Development	0.55	0.88	0.92	0.82	0.84	0.83	0.67	0.67		0.69	0.71	0.94	0.58	-0.66	0.52	-0.1	0.48	-0.18	0.1	0.93	-0.15	-0.14	-0.79	0.55
Ebitda	0.82	0.76	0.79	0.95	0.94	0.91	0.96	0.97	0.69		0.91	0.75	0.96	-0.74	0.71	0.07	0.58	-0.64	-0.29	0.8	-0.05	-0.04	-0.79	0.77
Cost Of Revenue	0.93	0.66	0.78	0.96	0.92	0.97	0.82	0.81	0.71	0.91		0.77	0.85	-0.55	0.58	0.13	0.42	-0.73	-0.31	0.82	-0.01	-0.03	-0.66	0.88
Total Operating Expenses	0.59	0.91	0.95	0.88	0.9	0.88	0.75	0.73	0.94	0.75	0.77		0.67	-0.68	0.58	-0.09	0.55	-0.17	0.0	0.98	-0.15	-0.17	-0.82	0.57
Income Before Tax	0.74	0.66	0.75	0.89	0.88	0.83	0.96	0.95	0.58	0.96	0.85	0.67		-0.64	0.77	0.02	0.65	-0.63	-0.18	0.75	-0.11	-0.03	-0.68	0.65
Total Other Income Expense Net	-0.33	-0.82	-0.64	-0.69	-0.74	-0.63	-0.82	-0.84	-0.66	-0.74	-0.55	-0.68	-0.64		-0.5	0.0	-0.5	0.12	0.24	-0.66	0.03	0.34	0.86	-0.35
Net Income	0.47	0.62	0.6	0.66	0.69	0.62	0.74	0.74	0.52	0.71	0.58	0.58	0.77	-0.5		-0.61	0.97	-0.31	-0.12	0.64	-0.71	-0.12	-0.61	0.37
Income Tax Expense	0.18	-0.16	-0.02	0.05	0.01	0.05	0.03	0.02	-0.1	0.07	0.13	-0.09	0.02	0.0	-0.61		-0.72	-0.28	-0.03	-0.1	0.98	0.15	0.12	0.22
Net Income From Continuing Ops	0.28	0.62	0.54	0.55	0.59	0.5	0.65	0.65	0.48	0.58	0.42	0.55	0.65	-0.5	0.97	-0.72		-0.1	-0.04	0.58	-0.77	-0.22	-0.6	0.2
Non Recurring	-0.81	-0.09	-0.24	-0.59	-0.51	-0.6	-0.49	-0.5	-0.18	-0.64	-0.73	-0.17	-0.63	0.12	-0.31	-0.28	-0.1		0.31	-0.31	-0.12	-0.24	0.15	-0.74
Non Operating Income Net Other	-0.39	-0.04	0.0	-0.18	-0.12	-0.17	-0.19	-0.21	0.1	-0.29	-0.31	0.0	-0.18	0.24	-0.12	-0.03	-0.04	0.31		0.05	0.03	-0.02	0.18	-0.41
Selling And Marketing Expenses	0.64	0.87	0.94	0.92	0.94	0.92	0.79	0.78	0.93	0.8	0.82	0.98	0.75	-0.66	0.64	-0.1	0.58	-0.31	0.05		-0.18	-0.1	-0.77	0.6
Tax Provision	0.03	-0.19	-0.09	-0.07	-0.09	-0.07	-0.07	-0.08	-0.15	-0.05	-0.01	-0.15	-0.11	0.03	-0.71	0.98	-0.77	-0.12	0.03	-0.18		0.09	0.16	0.08
Interest Income	0.18	-0.26	-0.13	-0.13	-0.17	-0.11	-0.16	-0.14	-0.14	-0.04	-0.03	-0.17	-0.03	0.34	-0.12	0.15	-0.22	-0.24	-0.02	-0.1	0.09		0.36	0.23
Net Interest Income	-0.53	-0.96	-0.78	-0.8	-0.84	-0.77	-0.81	-0.82	-0.79	-0.79	-0.66	-0.82	-0.68	0.86	-0.61	0.12	-0.6	0.15	0.18	-0.77	0.16	0.36		-0.54
Reconciled Depreciation	0.98	0.5	0.6	0.78	0.72	0.81	0.59	0.6	0.55	0.77	0.88	0.57	0.65	-0.35	0.37	0.22	0.2	-0.74	-0.41	0.6	0.08	0.23	-0.54

Click cells to compare fundamentals

Pacira Pharmaceuticals Account Relationship Matchups

Pacira Pharmaceuticals income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	5.7M	20.5M	13.6M	61.4M	75.6M	79.4M
Interest Expense	23.6M	25.7M	31.8M	40.0M	23.8M	16.1M
Selling General Administrative	71.1M	74.8M	88.3M	109.5M	116.4M	63.1M
Total Revenue	421.0M	420.8M	541.5M	666.8M	675.0M	708.7M
Gross Profit	314.3M	303.5M	401.3M	467.5M	433.0M	454.7M
Other Operating Expenses	385.3M	378.1M	408.7M	595.9M	587.7M	617.0M
Operating Income	38.1M	46.4M	131.1M	60.0M	87.3M	91.7M
Ebit	38.1M	46.4M	131.1M	60.0M	87.3M	91.7M
Research Development	72.1M	59.4M	55.5M	84.8M	76.3M	46.7M
Ebitda	43.8M	66.9M	144.6M	121.5M	162.9M	171.0M
Cost Of Revenue	106.7M	117.3M	140.3M	199.3M	242.0M	254.1M
Total Operating Expenses	278.6M	260.8M	268.4M	396.6M	345.7M	190.2M
Income Before Tax	(10.7M)	20.1M	56.4M	13.3M	61.7M	64.8M
Total Other Income Expense Net	(48.9M)	(26.3M)	(74.7M)	(46.7M)	(25.6M)	(24.3M)
Net Income	(11.0M)	145.5M	42.0M	15.9M	42.0M	44.1M
Income Tax Expense	268K	(125.4M)	14.4M	(2.6M)	19.7M	20.7M
Net Income From Continuing Ops	(11.0M)	145.5M	42.0M	15.9M	7.0M	7.3M
Non Operating Income Net Other	5.6M	2.4M	(590K)	(1.8M)	(2.0M)	(1.9M)
Net Income Applicable To Common Shares	(11.0M)	145.5M	42.0M	15.9M	18.3M	19.2M
Selling And Marketing Expenses	129.7M	118.7M	111.0M	145.0M	153.0M	106.6M
Tax Provision	268K	(125.4M)	14.4M	(2.6M)	2.9M	3.1M
Interest Income	7.4M	4.6M	896K	4.5M	10.8M	5.8M
Net Interest Income	(16.3M)	(21.0M)	(30.9M)	(35.4M)	(17.2M)	(18.0M)
Reconciled Depreciation	19.6M	19.9M	13.6M	91.5M	87.5M	91.9M

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pacira Pharmaceuticals using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Fix portfolios for free

When determining whether Pacira Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Pacira Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pacira Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pacira Pharmaceuticals Stock:

How To Invest In Pacira

Details

Is Pacira Stock a good investment?

Details

What is Pacira Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more information on how to buy Pacira Stock please use our How to Invest in Pacira Pharmaceuticals guide.

You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Complementary Tools for Pacira Stock analysis

When running Pacira Pharmaceuticals' price analysis, check to measure Pacira Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira Pharmaceuticals is operating at the current time. Most of Pacira Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pacira Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pacira Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Commodity Channel Use Commodity Channel Index to analyze current equity momentum
	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Money Managers Screen money managers from public funds and ETFs managed around the world
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules

Is Pacira Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacira Pharmaceuticals. If investors know Pacira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacira Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.291

Earnings Share

0.89

Revenue Per Share

14.603

Quarterly Revenue Growth

0.054

Return On Assets

0.0335

The market value of Pacira Pharmaceuticals is measured differently than its book value, which is the value of Pacira that is recorded on the company's balance sheet. Investors also form their own opinion of Pacira Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Pacira Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacira Pharmaceuticals' market value can be influenced by many factors that don't directly affect Pacira Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Pacira Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pacira Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacira Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Pacira Historical Income Statement

About Pacira Income Statement Analysis

Pacira Pharmaceuticals Income Statement Chart

Total Revenue

Other Operating Expenses

Total Operating Expenses

Pacira Pharmaceuticals income statement Correlations

Pacira Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Pacira Pharmaceuticals income statement Accounts

Becoming a Better Investor with Macroaxis

Build Optimal Portfolios

Align your risk with return expectations

Complementary Tools for Pacira Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ebit	+ 1.0	Operating Income
Gross Profit	+ 0.99	Total Revenue
Other Operating Expenses	+ 0.99	Total Revenue
Reconciled Depreciation	+ 0.98	Depreciation And Amortization
Other Operating Expenses	+ 0.98	Gross Profit
Selling And Marketing Expenses	+ 0.98	Total Operating Expenses

Net Interest Income	- 0.96	Interest Expense
Total Other Income Expense Net	- 0.84	Ebit
Net Interest Income	- 0.84	Gross Profit
Net Interest Income	- 0.82	Total Operating Expenses
Net Interest Income	- 0.82	Ebit
Total Other Income Expense Net	- 0.82	Operating Income